Due to health issues, this site is no longer maintained and will be shut down shortly.

FP:VLA Valneva

Valneva SE, a specialty vaccine company, engages in developing and commercializing vaccines for infectious diseases with unmet needs. Its portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT indicated for the prevention of Japanese encephalitis; and DUKORAL indicated for the prevention of cholera and in some countries prevention of diarrhea caused by ETEC. The company has various vaccines in development, including a vaccine against Lyme disease and single-shot vaccine against chikungunya. It has operations in Austria, Canada, France, Sweden, the United Kingdom, and the United States. The company has collaboration with Dynavax Technologies Corporation to advance vaccine development for COVID-19. Valneva SE was incorporated in 1999 and is headquartered in Nantes, France.This company has ADRs that trade in the U.S. as the symbol VALN.

4.63 EUR
As of 03/24/2023

Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Developed markets ex-US
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  France
Country of incorporation:  France
IPO date:  06/29/2007
Stock exchange:    Euronext Paris
Exchange country:   France
Market cap:   1,278,965,120 EUR
Current dividend yield:   0.00%
Sedol:      B03KGM0

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy